Fate Therapeutics Shares Outstanding 2012-2021 | FATE

Fate Therapeutics shares outstanding history from 2012 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Fate Therapeutics shares outstanding for the quarter ending June 30, 2021 were 0.094B, a 18.94% increase year-over-year.
  • Fate Therapeutics 2020 shares outstanding were 0.082B, a 20.82% increase from 2019.
  • Fate Therapeutics 2019 shares outstanding were 0.068B, a 21.34% increase from 2018.
  • Fate Therapeutics 2018 shares outstanding were 0.056B, a 33.86% increase from 2017.
Fate Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 82
2019 68
2018 56
2017 42
2016 32
2015 25
2014 20
2013 6
2012 1
2011 1
Fate Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 94
2021-03-31 93
2020-12-31 82
2020-09-30 87
2020-06-30 79
2020-03-31 76
2019-12-31 68
2019-09-30 67
2019-06-30 65
2019-03-31 65
2018-12-31 56
2018-09-30 54
2018-06-30 53
2018-03-31 53
2017-12-31 42
2017-09-30 41
2017-06-30 41
2017-03-31 41
2016-12-31 32
2016-09-30 32
2016-06-30 29
2016-03-31 29
2015-12-31 25
2015-09-30 29
2015-06-30 24
2015-03-31 21
2014-12-31 20
2014-09-30 20
2014-06-30 20
2014-03-31 20
2013-12-31 6
2013-09-30 1
2013-06-30 1
2013-03-31 1
2012-12-31
2012-09-30 1
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.173B $0.031B
Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29